The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
The FDA recently announced the approval of rilzabrutinib tablets for adults with persistent or chronic immune thrombocytopenia who did not respond to immunoglobulins, anti-D therapy, or corticosteroids.
...
Two-year data from the long-term phase 3 ALLEGRO-LT study suggest ritlecitinib maintains long-term clinical efficacy with a manageable safety profile in patients with moderate to severe alopecia areata.
...
A phase 3 trial shows that adding voclosporin to mycophenolate mofetil and low-dose glucocorticoids leads to higher rates of complete renal response and faster reduction in proteinuria for patients with...
Post hoc analyses of the phase 2 NOBILITY trial reveal that adding obinutuzumab to standard lupus nephritis therapy enhances kidney preservation and reduces glucocorticoid reliance.
In a multicenter, retrospective study, researchers evaluated time from NMOSD onset to serological diagnosis and factors associated with predicting shorter time to diagnosis.
A systematic review and meta-analysis examined the clinical differences between adult patients with neuromyelitis optica spectrum disorders and those with multiple sclerosis.
Using data from the Fibrotic Liver Disease Consortium, authors of a new study evaluated ursodeoxycholic acid’s impact on patients with primary biliary cholangitis and whether the effects differ across...
In a post hoc analysis of the ALLEGRO-2b/3 trial, investigators evaluated whether patients with alopecia areata who achieved clinically meaningful scalp hair regrowth experienced parallel improvements in...
